Marc Bonneville, PhD

Marc Bonneville, DVM and CNRS research director, is currently the CSO of Institut Merieux, a holding dedicated to the development of diagnostic and therapeutic tools in the fields of infectious diseases, cancer and food safety. He was formerly the director of the INSERM Cancer Research Center Nantes / Angers (France). In 1983 Dr. Bonneville began to study transplantation immunology in Nantes (France) and then switched during 1987 to 1989, to the analysis of mouse cellular immune responses during his postdoctoral training in S. Tonegawa’s laboratory (MIT, Boston). From 1990 to 2013 he has been heading a research group working on human cellular immune responses with a main focus on γδ and NKT cells, and virus-specific conventional T cell responses. He is a co-founder of Innate Pharma SA, a biotech company that implements new immunotherapies targeting innate lymphocytes in infectiology and oncology. Dr. Bonneville has authored around 200 scientific papers and 8 patents.

AGT on Social Media: